Newly Aligned Teams Sped US FDA’s Drug Quality Reviews Over Pandemic Hurdles
Realignment played key role in keeping assessments on track as COVID-19 buckled pharmaceutical supply and distribution chains and prevented inspections.
You may also be interested in...
OPQ Director Kopcha looks back at a year that travel restrictions made especially challenging for application reviews, site surveillance, IT support and sleep. And ahead to new challenges around supply chain transparency and resilience.
US FDA excludes chronic care products from list of medicines bolstered by domestic production investment and federal procurement requirements.
The Trump administration’s move to strengthen domestic manufacture of essential medicines raises a lot of questions – and industry’s ire.